AACR 2023 – Moderna's immunotherapeutic splash
This year’s AACR meeting promises a surprising amount of clinical data relevant to biopharma investors.
World ADC 2023 – targeting the folate receptor rises from the ashes
Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.
Pfizer rescues biotech
The $43bn deal for Seagen marks the biggest biopharma acquisition since the pre-crash takeouts of Allergan and Celgene.
Polivy adcom: no overall survival, no problem
A US adcom surprisingly backs Polivy’s front-line use, and blockbuster sales could follow.
Spotlight – Seeking target selectivity in achondroplasia
As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?
